<DOC>
	<DOCNO>NCT02907177</DOCNO>
	<brief_summary>This clinical study compare efficacy , safety , tolerability therapy ponesimod v placebo subject active RMS treat DMF ( Tecfidera® ) .</brief_summary>
	<brief_title>Clinical Study Compare Efficacy Safety Ponesimod Placebo Subjects With Active Relapsing Multiple Sclerosis Who Are Treated With Dimethyl Fumarate ( Tecfidera® )</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Dimethyl Fumarate</mesh_term>
	<criteria>Signed informed consent prior initiation studymandated procedure . Women childbearing potential must negative pregnancy test use reliable method contraception Presenting diagnosis MS define revise ( 2010 ) McDonald Diagnostic Criteria MS relapse course onset ( i.e. , relapsingremitting multiple sclerosis ( RRMS ) , secondary progressive multiple sclerosis ( SPMS ) superimpose relapse ) . Ongoing treatment DMF least 6 month prior screen ; Active disease 12 month prior screen least 3 month DMF treatment Ambulatory EDSS score 0 6.0 ( inclusive ) . Lactating pregnant woman woman intend become pregnant study . Presenting diagnosis MS progressive course onset ( i.e. , primary progressive MS progressive relapse MS ) . Evidence relapse MS onset within 30 day prior baseline EDSS assessment . Any circumstance condition , , opinion investigator , may affect full participation study compliance protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>